# Jazz Pharmaceuticals account plan

> Jazz Pharmaceuticals is a Dublin-based rare disease biopharma (sleep, epilepsy, oncology): $4,267.6 million 2025 revenue, about 2,890 employees.

## At a glance

Jazz Pharmaceuticals plc is a Dublin-headquartered biopharmaceutical company focused on rare disease, with marketed medicines in rare sleep disorders (Xywav, Xyrem), rare epilepsies (Epidiolex/Epidyolex) and rare cancers (Ziihera, Modeyso, Zepzelca, Rylaze, Vyxeos, Defitelio). It has direct commercial operations in the U.S., Europe, Australia and Canada and manufactures in Ireland, the U.K. and Italy; U.S. revenues were $3,831.6 million of the 2025 total. FY2025 total revenues were $4,267.6 million (+5%) with a net loss of $356.1 million, driven by acquired IPR&D and litigation settlements. It employed approximately 2,890 people at 31 December 2025, about 53% in the U.S.; Renee D. Gala is President and CEO.

## Business units

- **Neuroscience: rare sleep (Xywav, Xyrem)** (about 67% of 2025 total revenues ($2,878.5 million of product sales, computed)): Xywav, the largest product at $1,657.0 million in 2025 (41% of net product sales), treats narcolepsy and is the only FDA-approved therapy for idiopathic hypersomnia in adults; Xyrem declined 38% on high-sodium generic competition. In Q3 2026 Xywav sales rose 12% to $482.8 million with about 17,550 active patients.
- **Neuroscience: rare epilepsy (Epidiolex/Epidyolex)** (26% of 2025 net product sales ($1,059.2 million)): Cannabidiol oral solution for seizures in Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, reimbursed in more than 40 countries. Q3 2026 sales slipped 2% to $295.4 million; a capsule formulation NDA has a PDUFA date of 16 April 2027 and the Actio acquisition added ABS-1230 for KCNT1-related epilepsy.
- **Oncology** (about 26% of 2025 total revenues ($1,129.2 million of product sales, computed)): Rylaze, Zepzelca, Defitelio, Vyxeos, Modeyso and Ziihera, sold to hospitals and oncology clinics. Q3 2026 oncology sales were $387.1 million (Q3 2025: $287.8 million), with Zepzelca up 32% and Ziihera approved in first-line HER2-positive GEA on 25 August 2026.

## Strategic priorities

- **Ziihera launch in first-line GEA**: FDA approval on 25 August 2026 in first-line HER2-positive GEA, targeting 3,000 to 4,000 U.S. patients a year; Jazz puts Ziihera's peak sales potential at $3 billion to $5 billion.
- **Revenue diversification away from oxybates**: Xyrem plus high-sodium oxybate AG royalty revenue fell from 74% of total revenue in 2020 to 8% in 2025, with growth now driven by Modeyso, Ziihera and Epidiolex.
- **Rare disease business development**: Jazz looks at licensing, structured deals and outright M&A in rare disease; it acquired Chimerix in 2025 and Actio for $820 million in 2026.
- **Defending Xywav**: Management expects Xywav to remain foundational across NT1, NT2 and idiopathic hypersomnia, backed by Orange Book-listed patents to 2033 and 2037 and an IH patent to 2041.
- **Advancing the late-stage pipeline**: Phase 3 trials for zanidatamab in breast cancer (EmpowHER-BC-303) and dordaviprone in diffuse glioma (ACTION, readout expected in 1H27), plus Jazz's own orexin 2 receptor agonist JZP269.

## Latest results

In Q3 2026 Jazz reported record total revenues of $1,243.0 million, up 10% from $1,126.1 million, and $3,520.2 million for nine months. Xywav grew 12% and oncology sales reached $387.1 million, while Epidiolex/Epidyolex slipped 2%. The GAAP net loss was $483.4 million after $754.2 million of acquired IPR&D from the Actio acquisition. Full-year 2026 total revenue guidance was raised to $4,775-4,850 million from $4,600-4,750 million in August, nearly 13% growth at the midpoint.

## Investments and deals

- **Actio acquisition**: Closed in September 2026 for $820 million, adding ABS-1230 (JZP6979), a potential first-in-class therapy for KCNT1-related epilepsy.
- **Chimerix acquisition**: Acquired in 2025 for $944.2 million, bringing Modeyso, which reached about $200 million of sales and 725 patients since its August 2025 launch.
- **Saniona licence**: JZP053 (Kv7.2/Kv7.3 activator) licensed in August 2025 for $42.5 million upfront.
- **Financing and buybacks**: A $1.25 billion private placement of 1.875% exchangeable notes due 2032, $225 million of share repurchases, a new $500 million programme approved in October 2026, and the Term Loan B extended to May 2033.

## Challenges and risks

- **Oxybate competition**: Lumryz, authorized generics, approved high-sodium generics, Xywav ANDA filers and orexin 2 receptor agonists in development at several companies threaten the sleep franchise.
- **Drug pricing reform**: IRA Medicare negotiation, Medicaid rebate changes and CMS most-favoured-nation models, plus uncertainty on MFN pricing for Ziihera outside the U.S.
- **Tariffs on manufacturing**: Tariffs on pharmaceutical imports could hit margins as early as fiscal 2026 given manufacturing in Ireland, the U.K. and Italy; Jazz increased U.S. inventory in anticipation.
- **Debt load**: Long-term debt principal was $5.6 billion at 30 September 2026 against $2.9 billion of cash, cash equivalents and investments.
- **Oncology competition**: Amgen's IMDELLTRA is expected to be a headwind for Zepzelca in 2027, and Modeyso faces a more measured revenue pace in the near term.

## What leadership says

> "was a defining milestone for Jazz, establishing an important new source of growth" — Renee Gala, President and Chief Executive Officer, Q3 2026 earnings call, 2 November 2026, on the Ziihera first-line GEA approval

> "As we enter 2027, we have clear priorities, the financial strength to invest behind them and a strong track record of execution." — Renee Gala, President and Chief Executive Officer, Q3 2026 earnings call, 2 November 2026

> "We are highly engaged on the BD front, and I do expect us to have deals announced over the course of this year." — Renee Gala, President and Chief Executive Officer, Q1 2026 earnings call, 5 May 2026


## Where a supplier can help

- **Community oncology launch support**: Tied to the Ziihera launch: the commercial strategy broadens reach to community accounts, where about 80% of new ordering accounts sit, so field enablement, HCP engagement and data services are relevant.
- **Clinical trial services**: Tied to the late-stage pipeline: CRO, site and data services fit Phase 3 trials such as EmpowHER-BC-303 and ACTION and the registrational KYRON trial.
- **Supply chain resilience**: Tied to the tariff challenge: manufacturing, inventory and trade-compliance offers address a stated margin risk on Irish, U.K. and Italian production.
- **Patient support programmes**: Tied to defending Xywav: management credits JazzCares support services and the REMS for limiting generic erosion, so patient services and adherence tools fit.
- **Business development diligence**: Tied to rare disease business development: advisory, diligence and integration support match an active deal strategy after Chimerix and Actio.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for the fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm)

Annual report · 2026-02-24

- Jazz Pharmaceuticals plc is a Dublin-headquartered global biopharmaceutical company focused on rare disease, with leading therapies in epilepsies, cancers and sleep disorders; it reports one operating segment and derives most revenue from the U.S.
- FY2025 total revenues were $4,267.6 million (+5%), of which product sales, net $4,021.8 million; U.S. revenues were $3,831.6 million, Europe $341.1 million, all other $94.9 million.
- Xywav is the largest product: $1,657.0 million of net product sales (41% of total net product sales), about 16,175 patients at end-2025 (10,950 narcolepsy, 5,225 idiopathic hypersomnia); Epidiolex/Epidyolex added $1,059.2 million (26%).
- The rare oncology portfolio (Rylaze, Zepzelca, Defitelio, Vyxeos, Modeyso, Ziihera) totalled $1,129.2 million (+2%); Modeyso, approved August 2025 after the $944.2 million Chimerix Acquisition, sold $48.0 million in its launch year.
- Diversification away from Xyrem: in 2020, 74% of total revenue came from Xyrem; in 2025 Xyrem plus high-sodium oxybate AG royalty revenue was 8% of total revenue.
- The company posted a net loss of $356.1 million in 2025, driven by $947.9 million of acquired IPR&D (Modeyso and the Saniona licence) and $323.5 million of litigation settlements (Xyrem antitrust and Avadel).
- Balance sheet at 31 December 2025: $2.4 billion of cash, cash equivalents and investments, $5.4 billion of long-term debt principal, $885.0 million undrawn revolver; operating cash flow $1.4 billion.
- Pipeline priorities: zanidatamab (Ziihera) in first-line HER2-positive GEA after positive Phase 3 HERIZON-GEA-01 results, plus breast cancer and BTC trials; the Phase 3 ACTION trial for dordaviprone; early epilepsy and neuroscience assets.
- Key risks: oxybate competition (Lumryz, authorized generics, approved high-sodium generics, Xywav ANDA filers, orexin 2 receptor agonists in development), drug pricing reform (IRA, MFN models), and tariffs on its Irish, U.K. and Italian manufacturing.
- About 2,890 employees at end-2025, 53% in the U.S.; more than 740 support R&D. CEO Renee D. Gala, CFO Philip L. Johnson.

### [Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results (8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm)

Interim report · 2026-11-02

- Q3 2026 (quarter to 30 September) total revenues reached a record $1,243.0 million, +10% YoY; nine-month revenues $3,520.2 million.
- Full-year 2026 total revenue guidance raised to $4,775-4,850 million (from $4,600-4,750 million in August).
- Xywav net product sales rose 12% to $482.8 million, with about 425 net patient adds and about 17,550 active patients (11,375 narcolepsy, 6,175 idiopathic hypersomnia).
- Oncology sales were $387.1 million (Q3 2025: $287.8 million): Zepzelca +32% to $104.4 million on first-line maintenance uptake, Modeyso $61.1 million, Ziihera $20.6 million after FDA approval in first-line HER2+ GEA on 25 August 2026.
- Epidiolex/Epidyolex slipped 2% to $295.4 million on prior-year gross-to-net and inventory effects; a capsule formulation NDA has a PDUFA date of 16 April 2027.
- GAAP net loss of $483.4 million for the quarter after $754.2 million of acquired IPR&D for ABS-1230 (JZP6979) from the Actio acquisition; $34 million of restructuring expenses.
- Financing: $1.25 billion 1.875% exchangeable notes due 2032, $225 million of share buybacks, a new $500 million repurchase programme and a Term Loan B extended to May 2033.
- Cash, equivalents and investments of $2.9 billion against $5.6 billion of long-term debt principal; $1.3 billion cash from operations in nine months.

### [Jazz (JAZZ) Q3 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/11/02/jazz-jazz-q3-2026-earnings-call-transcript/)

Executive talk · Renee Gala, President and Chief Executive Officer · 2026-11-02

- CEO Renee Gala called the FDA approval and launch of Ziihera in first-line HER2-positive metastatic GEA "a defining milestone for Jazz"; peak sales potential for Ziihera is put at $3 billion to $5 billion.
- Record Q3 2026 revenue of $1.24 billion (+10%): oncology +35%, Xywav +12%; 2026 revenue guidance raised for the second quarter in a row to $4.775-4.85 billion, nearly 13% growth at the midpoint.
- Ziihera launch: target population of 3,000 to 4,000 U.S. patients a year; threefold rise in new ordering accounts in September, about 80% community clinics; 40% month-over-month rise in vial demand per selling day.
- Xywav: 17,550 active patients; high-sodium generics have had little impact; orexin 2 agonists may delay some new NT1 patients, but management sees Xywav as foundational in NT1, NT2 and IH.
- Modeyso: about $200 million of sales and 725 patients since launch; a "more measured revenue pace" in the near term as the launch moves into community oncology; $500 million U.S. peak expectation reaffirmed.
- Zepzelca grew 32% in first-line maintenance, but Amgen's IMDELLTRA is expected to be a headwind in 2027.
- Business development: Actio ($820 million) adds ABS-1230 for KCNT1 epilepsy; Gala wants more deals like Chimerix and Actio in rare disease.
- Chief Commercial Officer Samantha Pearce is retiring and will stay until a successor is appointed.

### [Jazz (JAZZ) Q1 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/05/05/jazz-jazz-q1-2026-earnings-call-transcript/)

Executive talk · Renee Gala, President and Chief Executive Officer · 2026-05-05

- Q1 2026 brought the highest-ever first-quarter revenue, more than 19% growth to $1.07 billion, with double-digit growth across all promoted brands; non-GAAP adjusted EPS was $6.34 and operating cash flow $408 million.
- Xywav sales rose 18% to $408 million with about 425 net patient adds (about 16,600 patients); Epidiolex grew 15% to $250 million on 16% volume growth.
- Zepzelca rose 60% to $101 million on first-line maintenance uptake; Modeyso sold $41 million with about 500 patients treated since launch, supporting a $500 million U.S. peak.
- CEO Renee Gala expected Ziihera to become "the HER2-targeted therapy of choice" in first-line HER2-positive GEA (PDUFA 25 August 2026).
- 2026 revenue guidance was reaffirmed at $4.25-4.5 billion, assuming second-half competition in sleep from high-sodium generics and wake-promoting agents.
- Gala: "I do expect us to have deals announced over the course of this year"; Jazz is looking at licensing, structured deals and outright M&A in rare disease, with $2.9 billion of cash and investments.
- Defending Xywav: Orange Book-listed patents to 2033 and 2037 and an IH patent to 2041; R&D chief Robert Iannone sees orexins as complementary to Xywav.
- Zepzelca patents extend to 2040; suits against five ANDA filers impose a stay of up to 30 months.

## Questions about Jazz Pharmaceuticals

### What does Jazz Pharmaceuticals do?

Jazz develops and sells medicines for rare diseases in sleep disorders, epilepsy and oncology, including Xywav, Epidiolex, Ziihera and Modeyso.

### What was Jazz Pharmaceuticals' revenue in 2025?

Total revenues were $4,267.6 million in 2025, up 5%; 2026 guidance is $4,775-4,850 million.

### How many employees does Jazz Pharmaceuticals have?

Approximately 2,890 at 31 December 2025, about 53% in the U.S.; more than 740 support R&D.

### Who leads Jazz Pharmaceuticals?

Renee D. Gala is President and CEO and Philip L. Johnson is CFO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
